An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer
This study will provide treatment with erlotinib to participants with advanced NSCLC who have received at least one course of standard chemotherapy or radiation therapy, or who are not medically suitable for either. Efficacy and safety will be monitored throughout the study.
Inclusion Criteria:
Exclusion Criteria:
Homburg/Saar, 66424, Germany
Haidari, 124.61, Greece
Feltre - Bl, 32032, Italy
Capelle Ad Yssel, 2906 ZC, Netherlands
Bundang City, 463-802, South Korea
Kyunggi-do, 411-769, South Korea